Dupixent Lawsuit

DUPIXENT Lawsuit Overview

Dupixent (dupilumab), a widely prescribed medication for eczema and other inflammatory conditions, is now under scrutiny. Patients across the country are coming forward after developing Cutaneous T-Cell Lymphoma (CTCL), a rare and potentially life-threatening blood cancer, shortly after beginning treatment.

Medical experts have reported a troubling pattern. Individuals who started Dupixent for what seemed like routine skin issues were later diagnosed with CTCL. Lawsuits allege that the drug’s manufacturers failed to properly warn patients and healthcare providers about this serious risk.

Act now. Your time to file a claim may be limited.
Call us today for a free, confidential case review.

KEY TAKEAWAYS

• The first known Dupixent lawsuit alleges the drug caused or accelerated fatal T-cell lymphoma, marking a pivotal moment for patients and families
• Plaintiffs claim the manufacturers failed to warn about the risks of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).
• Case reports and retrospective studies show a significantly higher diagnosis rate of CTCL among Dupixent users often misread as eczema flares, delaying treatment.
• The FDA is reviewing adverse event signals; Dupixent’s label does not currently warn about T-cell lymphoma
• If you develop CTCL or related T-cell lymphomas after Dupixent, you may qualify for compensation. No win, no fee.

DUPIXENT LAWSUIT TIMELINE

• October 17, 2025: In Tennessee, a mother files a wrongful death lawsuit on behalf of her late daughter’s estate, alleging that Dupixent injections caused fatal T-cell lymphoma. Chandra Richardson v. Sanofi-Aventis and Regeneron seek compensation for medical expenses, pain, and emotional suffering, claiming the companies failed to warn of the risk.
• October 2, 2025: After receiving numerous adverse event reports from Dupixent users diagnosed with CTCL, the FDA confirms that it is actively investigating whether regulatory actions such as label changes or recalls are necessary. Meanwhile, patients begin filing legal claims nationwide.
• June 20, 2025: Despite growing safety concerns, the FDA authorizes Dupixent to treat bullous pemphigoid, a painful blistering skin disease, making it the only targeted therapy available for BP patients

WHO CAN FILE A DUPIXENT LAWSUIT? 

• Used Dupixent (dupilumab) after 2017 for atopic dermatitis/eczema, asthma, COPD, CRSwNP, EoE, CSU, BP, or PN.
• Were later diagnosed with a T-cell lymphoma, including:
• CTCL (Mycosis Fungoides, Sézary Syndrome)
• PTCL (and subtypes such as ALCL, SPTCL, lymphomatoid papulosis, NK/T-cell lymphoma, adult T-cell leukemia/lymphoma, TFH-type PTCL
• Have documentation connecting diagnosis timing to Dupixent use (often 3-6+ months of therapy).

NOT SURE IF YOU QUALIFY? 

EVIDENCE NEEDED FOR A DUPIXENT LAWSUIT

• Medical Records: Dermatology/oncology notes, biopsy/pathology, staging, imaging, treatment plans.
• Dupixent Records: Prescriptions, injection logs, duration/dose, office notes, pharmacy receipts.
• Symptom Timeline: Onset/worsening of rashes, plaques, pruritus, night sweats, lymph node swelling, weight loss.
• Supporting Proof: Photos, MyChart downloads, packaging, witness statements.
• Financial Impact: Bills, insurance EOBs, wage loss, disability claims, employer letters.

Connect2Attorney offer free case reviews and work on a no-win, no-fee basis. Our experienced team in mass torts can help you gather medical records, assess your eligibility, and file your claim on time.

Take Action Today

In most states, you generally have one to two years from the date of diagnosis or discovery to file a Dupixent lawsuit. Time limits vary by state and case type, so it’s important to act promptly to protect your rights.